Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05935956 · ClinicalTrials.gov registry record

Safety and Effectiveness of Magnetic Peripheral Nerve Stimulation for the Treatment of Chemotherapy Induced Neuropathy

A clinical trial of Neuropathic Pain and Chemotherapy-induced Peripheral Neuropathy, sponsored by NeuraLace Medical.

Completed
Registry status
14
Enrollment target
1
Study location

NCT05935956 is a study of Neuropathic Pain and Chemotherapy-induced Peripheral Neuropathy that has completed, run by NeuraLace Medical. The registered enrollment target is 14 participants, below the 101-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05935956, a study of Neuropathic Pain and Chemotherapy-induced Peripheral Neuropathy, has completed, sponsored by NeuraLace Medical.

COMPLETED
Registry status
14 participants
Enrollment target
1
Study location

Study Summary

Assess the safety and effectiveness of Axon Therapy in the treatment of chemotherapy-induced neuropathy

Interventions

  • DEVICE Magnetic Peripheral Nerve Stimulation

Study Locations (1)

North Carolina

  • Carolinas Pain Institute and Center for Clinical Research - Winston-Salem

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2023-06-09
Est. Completion 2023-12-21

Sponsor

NeuraLace Medical

3 total trials

What the Registry Record Tells You About NCT05935956

The ClinicalTrials.gov registry entry for NCT05935956 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (86% lower). The listed sponsor is NeuraLace Medical, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Neuropathic Pain appearing as the primary indexed condition, and to 1 intervention - of which Magnetic Peripheral Nerve Stimulation is the first listed.

NCT05935956 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05935956 about?

NCT05935956 is a clinical study titled "Safety and Effectiveness of Magnetic Peripheral Nerve Stimulation for the Treatment of Chemotherapy Induced Neuropathy". Assess the safety and effectiveness of Axon Therapy in the treatment of chemotherapy-induced neuropathy

What is the current status of trial NCT05935956?

This trial is currently completed. The enrollment target is 14 participants. The study started on 2023-06-09. Estimated completion is 2023-12-21.

What conditions does trial NCT05935956 study?

This clinical trial studies the following conditions: Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy, Neuralgia.

What interventions are being tested in trial NCT05935956?

The interventions under investigation include: Magnetic Peripheral Nerve Stimulation (DEVICE).

Who is sponsoring clinical trial NCT05935956?

This trial is sponsored by NeuraLace Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05935956 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neuropathic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.